FDA approves orphan drug designation
February 21, 2014
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request.
Read the official press release here
Latest press releases
2024-09-01 19:27
IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.
2024-08-30 18:38
IBT's phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality
Regulatory
MAR
2024-08-28 08:30
Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024
Regulatory
2024-08-15 16:44
Patent for Infant Bacterial Therapeutics has been approved in the USA
Regulatory
MAR
Contact | info@ibtherapeutics.com
© Copyright Infant Bacterial Therapeutics AB 2024